SOUTH SAN FRANCISCO, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia” or the “Company”), a
clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular
diseases, today announced that it has commenced a proposed underwritten public offering of 3,500,000 shares of its common stock.
All shares of common stock will be offered by MyoKardia. In addition, MyoKardia expects to grant the underwriters a 30-day option
to purchase an additional 525,000 shares of common stock at the public offering price, less the underwriting discount.
MyoKardia anticipates using the net proceeds from the offering, together with its existing cash and cash equivalents, to fund
research and development activities for its development programs, including, but not limited to, its ongoing and planned clinical
trials for mavacamten (formerly MYK-461) and MYK-491, its ongoing preclinical, discovery and research programs and the expansion of
its platform, and for working capital and other general corporate purposes.
J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the proposed offering. BMO
Capital Markets Corp. is also acting as a bookrunner for the proposed offering. The offering is subject to market and other
customary closing conditions, and there can be no assurance as to whether or when the offering may be completed.
The shares described above are being offered by MyoKardia pursuant to a shelf registration statement on Form S-3, including a
base prospectus, that was previously filed by MyoKardia with the Securities and Exchange Commission (SEC) and that was
declared effective on January 19, 2017. A preliminary prospectus supplement and accompanying prospectus relating to the offering
will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying
prospectus relating to this offering, when available, may be obtained by contacting: J. P. Morgan Securities LLC,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling toll-free (866)
803-9204; or Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long
Island Avenue, Edgewood, NY 11717, or by telephone at (631) 274-2806 or by fax at (631) 254-7140. The final terms of the
offering will be disclosed in a final prospectus supplement to be filed with the SEC.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.
About MyoKardia
MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and
commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus is on the
treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical
defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic
programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy (HCM),
and dilated cardiomyopathy (DCM). MyoKardia’s most advanced product candidate is mavacamten (formerly MYK-461). Mavacamten is a
novel, oral, allosteric modulator of cardiac myosin that reduced hypercontractility in Phase 1 clinical studies of HCM patients. In
April 2016, the U.S. Food and Drug Administration granted Orphan Drug Designation for mavacamten for the treatment of symptomatic
oHCM, a subset of HCM. MyoKardia is currently studying mavacamten in PIONEER-HCM. MYK-491, MyoKardia’s second product candidate, is
designed to increase the overall extent of the heart’s contraction in DCM patients by increasing cardiac contractility. MyoKardia
is currently evaluating MYK-491 in a Phase 1 study in healthy volunteers. A cornerstone of the MyoKardia platform is the Sarcomeric
Human Cardiomyopathy Registry (SHaRe), a multi-center, international repository of clinical and laboratory data on individuals and
families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia’s mission is to change the world for patients
with serious cardiovascular disease through bold and innovative science.
Forward-Looking Statements
Statements we make in this press release may include statements which are not historical facts and are considered
forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, which are usually identified by the use of words such as "anticipates," "believes," "estimates,"
"expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions.
We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in
Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of
complying with those safe harbor provisions. These forward-looking statements, including references to MyoKardia’s expectations
regarding the completion, timing and size of its proposed public offering, its expectations with respect to granting the
underwriters a 30-day option to purchase additional shares and the anticipated use of proceeds therefrom, reflect our current views
about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us
and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as
reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions,
expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in
the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including,
without limitation, risks associated with the development and regulation of our product candidates, as well as those set forth in
our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 and our other filings with the SEC. Except as required by
law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future
events or otherwise.
Investor Contact: Beth DelGiacco Stern Investor Relations, Inc. 212-362-1200 beth@sternir.com Media Contact: Steven Cooper Edelman 415-486-3264 steven.cooper@edelman.com
